No Change In Pharmacokinetics Of ADHD Medication VYVANSE CII When Coadministered With Prilosec

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE® (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC® 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated.

More: continued here

Filed under: Acid Reflux/GERD on June 1st, 2009